- Conditions
- Acute Myeloid Leukemia
- Interventions
- AZD1152, LDAC (low dose cytosine arabinoside)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Interventions
- human myeloid progenitor cells, G-CSF
- Biological · Drug
- Lead sponsor
- Cellerant Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 10
- States / cities
- La Jolla, California • San Francisco, California • Stanford, California + 7 more
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
- Interventions
- KRT-232, Cytarabine, Decitabine
- Drug
- Lead sponsor
- Kartos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- trebananib, cytarabine, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Rochester, New York
- Conditions
- Leukemia
- Interventions
- Lenalidomide, Rituximab, Fludarabine, Cyclophosphamide, NK Cells, Cytarabine
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia, AML, Childhood
- Interventions
- Cytarabine, Daunorubicin, Erwinase, Etoposide, Gemtuzumab ozogamicin, Stem cell transplantation (SCT), Sorafenib
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Myelogenous Leukemia, AML, Advanced Myelodysplastic Syndromes, MDS
- Interventions
- Pevonedistat, Cytarabine
- Drug
- Lead sponsor
- Justin Watts, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
- Interventions
- Iomab-B, Conventional Care, HCT
- Drug · Procedure
- Lead sponsor
- Actinium Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 22
- States / cities
- Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
- Conditions
- Leukemia
- Interventions
- BMS-936564, Cytarabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orlando, Florida • Louisville, Kentucky + 6 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
- Interventions
- amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Kankakee, Illinois
- Conditions
- Acute Monocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Cytarabine, Echocardiography, Lumbar Puncture, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax
- Drug · Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida • Portland, Oregon
- Conditions
- Myelodysplasia, Leukemia
- Interventions
- chemotherapy
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia
- Interventions
- PRI-724
- Drug
- Lead sponsor
- Prism Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Lintuzumab (SGN-33), Low dose cytarabine, Placebo
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 20
- States / cities
- Mobile, Alabama • Beverly Hills, California • Glendale, California + 16 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Peg Interferon Alpha 2b (Peg Intron), Ara-C (cytosine arabinoside)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Myeloproliferative Diseases
- Interventions
- Clofarabine, Cytarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myelodysplastic Syndromes
- Interventions
- filgrastim, clofarabine, cytarabine, microarray analysis, biopsy
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Interventions
- 5-Azacytidine, Ara-C, Valproic Acid (VPA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Arsenic trioxide, Low-dose cytarabine alone
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more
- Conditions
- Pediatric, Hodgkin's Disease
- Interventions
- COPP/ABV, intensive chemo with concurrent growth factor
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Myeloid, Myelodysplastic Syndromes
- Interventions
- Gleevec, Ara-C
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Cladribine, Cytarabine, Decitabine, azacitidine or decitabine, Venetoclax
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Azacitidine, Cytarabine, Gemtuzumab Ozogamicin, Daunorubicin Hydrochloride, Fludarabine Phosphate, Idarubicin Hydrochloride, Mitoxantrone Hydrochloride, Etoposide, Gilteritinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 10
- States / cities
- Madera, California • Orange, California • San Diego, California + 7 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- Capivasertib, Venetoclax, Rituximab, Blinatumomab, Nelarabine, mini-hyperCVD
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois